CCR5 antagonists have different conformational requirements for the transition to the most thermodynamically stable CCR5 receptor: antagonist complex.

被引：0
作者：
Swinney, DC [1 ]
Beavis, P [1 ]
Kondru, RK [1 ]
Dioszegi, ME [1 ]
Gee, P [1 ]
Zhang, J [1 ]
Sankuratri, S [1 ]
Mirzadegan, T [1 ]
机构：
[1] Roche Palo Alto, Palo Alto, CA 94304 USA
来源：
FASEB JOURNAL | 2006年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A918 / A919
页数：2
相关论文
共 50 条
  • [21] Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker
    Arribas Lopez, Jose R.
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2008, 26 : 23 - 27
  • [22] Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists
    Saita, Y
    Kondo, M
    Miyazaki, T
    Yamaji, N
    Shimizu, Y
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 518 (2-3) : 227 - 233
  • [23] Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc
    Latinovic, Olga
    Szmacinski, Henryk
    Schneider, Kate
    Lakowicz, Joseph
    Heredia, Alonso
    Redfield, Robert
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 : 82 - 82
  • [24] Treatment with CCR5 antagonists: Which patient may have a benefit?
    Mueller, M. C.
    Bogner, J. R.
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 441 - 452
  • [25] Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc
    Latinovic, Olga
    Schneider, Kate
    Szmacinski, Henryk
    Lakowicz, Joseph R.
    Heredia, Alonso
    Redfield, Robert R.
    [J]. ANTIVIRAL RESEARCH, 2014, 112 : 80 - 90
  • [26] Comparative Docking Study of Anibamine as the First Natural Product CCR5 Antagonist in CCR5 Homology Models
    Li, Guo
    Haney, Kendra M.
    Kellogg, Glen E.
    Zhang, Yan
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (01) : 120 - 132
  • [27] Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5
    Ogilvie, P
    Bardi, G
    Clark-Lewis, I
    Baggiolini, M
    Uguccioni, M
    [J]. BLOOD, 2001, 97 (07) : 1920 - 1924
  • [28] Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist
    Nayak, Sunil U.
    Cicalese, Stephanie
    Tallarida, Chris
    Oliver, Chicora F.
    Rawls, Scott M.
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2020, 83 : 288 - 292
  • [29] CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1
    Lorenzen, Thore
    Stoehr, Albrecht
    Walther, Irene
    Plettenberg, Andreas
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 419 - 425
  • [30] Docking and CoMFA study on novel human CCR5 receptor antagonists
    Jahan B. Ghasemi
    Maryam Nouri
    [J]. Medicinal Chemistry Research, 2013, 22 : 1356 - 1364
12345